Faruqi & Faruqi, LLP Is Seeking More Cash For The Shareholders Of Medicis Pharmaceutical Corp. (MRX)

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medicis Pharmaceutical Corp. (“Medicis” or the “Company”) (NYSE: MRX) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Valeant Pharmaceuticals International Inc. (NYSE: VRX) in an all-cash deal valued at approximately $2.6 billion. Under the terms of the proposed transaction, Medicis’ stockholders will receive $44 in cash for each share of Medicis they own, while according to Yahoo! Finance, at least one financial analyst has set a price target of $45 for Medicis.